Horizon Pharma is a drug manufacturers - general business based in the US. Horizon Pharma shares (HZNP) are listed on the NASDAQ and all prices are listed in US Dollars. Horizon Pharma employs 2,190 staff and has a trailing 12-month revenue of around $3.6 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $110.76 |
| 200-day moving average | $108.06 |
| Wall St. target price | $116.50 |
| PE ratio | 61.8617 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $1.88 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Horizon Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Horizon Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Horizon Pharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 62x. In other words, Horizon Pharma shares trade at around 62x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Horizon Pharma's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Horizon Pharma's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Horizon Pharma's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $669.2 million.
The EBITDA is a measure of a Horizon Pharma's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $3.6 billion |
|---|---|
| Operating margin TTM | 17.68% |
| Gross profit TTM | $2.8 billion |
| Return on assets TTM | 4.44% |
| Return on equity TTM | 8.54% |
| Profit margin | 12.02% |
| Book value | $23.20 |
| Market Capitalization | $26.6 billion |
TTM: trailing 12 months
We're not expecting Horizon Pharma to pay a dividend over the next 12 months.
Over the last 12 months, Horizon Pharma's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Horizon Pharma's is 1.0114. This would suggest that Horizon Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc. ; Halozyme Therapeutics, Inc. ; Arrowhead Pharmaceuticals, Inc.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.